Wealth Marketing AI runs compliant paid acquisition for US research peptide brands whose ads get rejected and accounts restricted. We write creative that says what the product is and nothing it is not, build landing pages for review, fix account hygiene and tracking, and report weekly. Flat $5,000 a month, month to month.
Peptide brands get held to the policy line harder than almost any category. We build the ads, the pages and the account hygiene that pass review on their own, and we run the campaigns. Flat $5,000 a month. No tricks to get around review, ever.
"Healing." "Weight." "Dose." Each one moves the ad from what the product is to what it does to a person, and that is the exact line a reviewer is trained to catch. The vial saying research use only does not help if the ad says otherwise. Then the page gets opened, and it says the same things, louder.
An ad account you cannot keep is not an acquisition channel.
We run paid acquisition for a research peptide brand today, with per-SKU creative and a compliance-first creative system: no health claims, no dosing, no human-use language.
Behind it is a senior media buyer who has managed $500K+ a month across Google, Meta and TikTok, in categories where platforms and regulators make advertising hard. The brand stays unnamed until it says otherwise. No numbers are attached to it, on purpose.
Rejections get logged, root-caused and fixed in the rules that produce every ad and every page, so the next SKU and the next variation come out clean. When a compliant ad is still flagged, it gets a proper appeal, not a resubmit.
Step 01 removes the products we will not advertise: GLP-1 compounds and PT-141 are off limits in everything we produce, whatever else is in the catalog.
We publish the policy text rather than asking you to take our word for it: can you advertise research peptides on Meta and Google in 2026? quotes and links every Meta and Google policy line that decides this, plus the FDA letters that explain why a research use only disclaimer does not save a page.
If the ask is to get around enforcement in any form, we decline the engagement. It is the fastest way to lose the account, and we would be the ones losing it for you.
The check flags the phrases that get research peptide ads rejected: human-use language, dosing, disease and treatment claims, weight, anti-aging, muscle, before and after, named drugs, personal-use prompts. Each flag comes with a plain explanation and a compliant rewrite where one is obvious. It runs in your browser. Nothing you paste leaves this page.
Client-side only. No server, no form, no storage. Close the tab and it is gone.
US brands that sell research peptides for research use only from their own website, already running or trying to run paid ads, and tired of rejected ads and restricted accounts. Founders and heads of growth who want the account to survive, not the next trick.
A compliance-first creative system per SKU (every ad says what the product is and nothing it is not: no health claims, no dosing, no human-use language), landing pages built to pass review, ad account structure and hygiene, tracking that fires at the right step, and a weekly one-page report with a 20-minute call. We run the campaigns.
Anything whose purpose is to get around platform review. The reviewer and the buyer see the same page. One account per platform, kept clean, never replaced by another. The product is described as exactly what it is. If that is not the engagement you want, we are not the right call. We also do not produce creative for GLP-1 compounds or PT-141, whatever else the brand sells.
A flat $5,000 a month, month to month, no long contract. You fund the ad spend directly in ad accounts you own, and that spend is separate from the fee. Everything we build stays with you.
No. Nobody can guarantee a platform decision, and anyone who does is guessing. What we do is remove the reasons peptide ads get rejected, log the ones that still are, fix the cause in the system rather than in one ad, and file a proper appeal when a compliant ad is wrongly flagged.
GLP-1 compounds and PT-141. They are off limits in every ad and page we produce. If those are the only products worth advertising in your catalog, we are not a fit.
A free tool on this page. Paste an ad or the text of a landing page and it flags the phrases that trigger rejections in this category, with a plain explanation and a compliant rewrite where one is obvious. It runs in your browser. Nothing you paste is sent anywhere. Run it, or book a call and we will run it on your live ads with you.
Questions and answers
Plain answers to the questions a research peptide brand asks before a call: what it costs, how it is paid, what is included, who it is for, how long it takes, what can go wrong, and what makes it different.
Last updated .
A flat $5,000 a month in USD, month to month, with no long contract. You fund the ad spend directly in ad accounts you own, and that spend is separate from the fee. Everything we build, from pages to creative to tracking, stays with you.
| Fee | $5,000 a month, flat, in USD, month to month. |
|---|---|
| Ad spend | Yours, funded directly inside ad accounts you own. |
| Contract | Month to month. No long tie-in. |
| Ownership | Creative, landing pages, tracking and account structure stay with the brand. |
| Reporting | One page every week, plus a 20-minute call. |
| Off limits | GLP-1 compounds and PT-141, plus any dosing, human-use, disease or before-and-after language. |
Monthly, flat, for services rendered. There is no percentage of revenue and no per-order fee. Media is billed to you by the platforms inside your own accounts, so nothing routes through us and the billing history stays on your own business record.
A compliance-first creative system per SKU, landing pages built to pass review, ad account structure and hygiene, tracking that fires at the right step, a proper appeal when a compliant ad is wrongly flagged, and a weekly one-page report with a 20-minute call. We run the campaigns.
US brands selling research peptides for research use only from their own website, already running or trying to run paid ads, and tired of rejected ads and restricted accounts. Founders and heads of growth who want the account to survive rather than the next trick to work once.
Plan two to three weeks from signed to live: a policy audit and page rebuild first, then creative, then a small controlled launch. Review decisions arrive in hours or days, and a rebuilt page usually has to be reviewed again, so the launch is staged deliberately rather than all at once.
No one can promise a platform decision, and an account carrying prior violations carries that history into every review. Compliant ads still get flagged wrongly. We remove the reasons for rejection, log the ones that happen anyway, fix the cause in the system rather than in one ad, and appeal.
The reviewer and the buyer see the same page. One account per platform, kept clean. Nothing built to get around review, and no personal-use language. We treat platform policy as the constraint the business is built inside, not an obstacle to route around.
GLP-1 compounds and PT-141 are off limits in every ad and every page we produce, whatever else a catalogue sells. We also refuse dosing, human-use language, disease or treatment claims, and before-and-after framing. If those are the only products worth advertising for you, we are not a fit.
On the call we look at your rejection history, your catalog, your pages and whether it is a fit. It ends with a yes, a no, or a booked next step, never a proposal that goes nowhere. Flat $5,000 a month, month to month.